Bondronat 50 mg FC tablets.
PDF Leaflet Revision Date: 05 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of skeletal complications in breast cancer with bone metastases.
Dosage (summary)
50 mg daily; adjust for renal impairment.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to lack of clinical experience.
Key Drug Interactions
- Calcium supplements
- NSAIDs
- Aminoglycosides
Contraindications
- Hypersensitivity to ibandronic acid
- Hypocalcaemia
- Oesophageal abnormalities
- Inability to sit upright
Common side effects
- Hypocalcaemia
- Oesophagitis
- Dyspepsia
- Nausea
Counselling Points
- Take after overnight fast
- Avoid lying down for 60 mins post-dose
- Report any esophageal symptoms
Serious warnings
- Osteonecrosis of the jaw
- Atypical femur fractures
- Gastrointestinal irritation
Important Disclaimer
The Bondronat 50 mg FC tablets. professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
